Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Nanoparticle Formulation Market 2023 to 2035: Lipid Nanoparticle Formulation is Driving Partnership Activity

      Research and Markets Logo

      News provided by

      Research and Markets

      Jul 04, 2023, 21:15 ET

      Share this article

      Share this article


      DUBLIN, July 4, 2023 /PRNewswire/ -- The "Nanoparticle Formulation Market 2023-2035" report has been added to  ResearchAndMarkets.com's offering.


      The global nanoparticle formulation market was estimated to be worth USD 5.1 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9.4% during the forecast period.

      This report features an extensive study of the current market landscape, market size and future opportunities associated with the nanoparticle formulation technologies and services market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the nanoparticle formulation market are briefly discussed below.

      Over the years, nanoparticles have emerged as a versatile drug delivery system for the controlled, targeted delivery of therapeutics for the treatment of several diseases. Owing to their inherent properties, such as small size, multifunctional behavior and surface tailorability, these novel nanoparticle drug delivery systems confer several advantages over the conventional drug delivery systems.

      The ongoing advancements in nanoparticle technology have paved way for the development of safe and effective nano-based drugs with improved treatment specificity, stability, water solubility, and high penetration and retention time. In addition, nanoparticles are widely adopted in other healthcare-associated segments, such as diagnostic assays, dentistry, tissue-engineered constructs and medical imaging.

      However, nanoparticle development and nanoparticle formulation is a complex and cost-intensive process. The nanoparticles need to be engineered through advanced nanoparticle formulation and nanoparticle manufacturing techniques that require specialized technical expertise.

      Therefore, researchers and drug developers are actively relying on contract service providers having the technical expertise and nanoparticle technology to develop and formulate the desired nanoparticles. Further, driven by the growing demand for nanoparticle-based therapeutics, the nanoparticle formulation market is anticipated to witness substantial growth during the forecast period.

      Rising Interest in Nanoparticle-based Vaccines to Drive Nanoparticle Formulation Market

      High mortality and morbidity rates caused due to coronavirus infection prompted the researchers and drug developers to develop safer, effective Covid vaccines. They are actively investigating the role of mRNA vaccines for the prevention and treatment of this life-threatening disease. The use of nanoparticles in vaccines contribute to the overall immunomodulatory properties, making them suitable candidates for the formulation of vaccines.

      Lately, mRNA-LNP vaccines have demonstrated their potential as prophylactic Covid vaccines. It is interesting to highlight that, in 2020, Pfizer-BioNTech entered into an agreement with Acuitas Therapeutics to license Acuitas Therapeutic's lipid nanoparticle formulation technology to develop mRNA Covid vaccines. Further, in January 2022, both the companies expanded their agreement for the utilization of LNP technology in order to develop various vaccines and therapeutics.

      Benefits of Formulating Drugs with Nanoparticles

      The growing interest in using nanoparticles for therapeutic purposes can be attributed to their ability to encapsulate multiple drugs, enhanced drug bioavailability and protection from physiological barriers. The pharmaceutical industry has witnessed a steady rise in the number of approved drugs based on nanoparticle formulations. These nanopharmaceuticals can serve both as the delivery vehicle and therapeutic agent to aid in the treatment of a variety of disease conditions, including cancer, cardiovascular disorders, neurological disorders and infectious diseases.

      In case of cancer, nanoparticles are being developed to increase the permeability and retention of chemotherapeutic agents and to aid in the delivery of both diagnostic and therapeutic agents. In 2018, the European Medicines Agency (EMA) approved Vyxeos (developed by Jazz Pharmaceuticals) for the treatment of acute myeloid leukemia. The drug is a LNP-based nanoformulation that has high circulation time in bone marrow.

      Lipid Nanoparticle Formulation is Driving the Partnership Activity in the Overall Nanoparticle Formulation Market

      Several stakeholders have been forging alliances with other industry / non-industry players in nanoparticle formulation market for technology licensing, research and development and product development purposes. It is worth highlighting that, since 2018, over 160 strategic partnerships have been inked in the nanoparticle formulation industry.

      Owing to several advantages of lipid nanoparticles in therapeutics, the stakeholders are also acquiring other industry players specializing in various aspects of lipid nanoparticle formulation in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2022, Merck acquired Exelead, a biopharmaceutical CDMO, to enhance its LNP formulation capabilities and operate as a one-stop-shop in the LNP formulation market.

      At present, more than 40 companies engaged in providing lipid nanoparticle formulation service. Examples of top players engaged in this market (which have also been captured in this report) include BOC Sciences, CordenPharma, Curia, Emergent CDMO and Fujifilm.

      Key Topics Covered:

      1. PREFACE

      2. EXECUTIVE SUMMARY

      3. INTRODUCTION

      4. TECHNOLOGY LANDSCAPE

      5. SERVICE PROVIDERS LANDSCAPE

      6. TECHNOLOGY COMPETITIVENESS ANALYSIS

      7. COMPANY COMPETITIVENESS ANALYSIS

      8. COMPANY PROFILES
      8.1. Chapter Overview
      8.2. Ascension Sciences
      8.2.1. Company Overview
      8.2.2. Technology Portfolio
      8.2.3. Service Portfolio
      8.2.4. Recent Developments and Future Outlook
      8.3. DIANT Pharma
      8.3.1. Company Overview
      8.3.2. Technology Portfolio
      8.3.3. Service Portfolio
      8.3.4. Recent Developments and Future Outlook
      8.4. ExonanoRNA
      8.4.1. Company Overview
      8.4.2. Technology Portfolio
      8.4.3. Service Portfolio
      8.4.4. Recent Developments and Future Outlook
      8.5. Nanoform
      8.5.1. Company Overview
      8.5.2. Technology Portfolio
      8.5.3. Service Portfolio
      8.5.4. Recent Developments and Future Outlook
      8.6. NanoVation Therapeutics
      8.6.1. Company Overview
      8.6.2. Technology Portfolio
      8.6.3. Service Portfolio
      8.6.4. Recent Developments and Future Outlook
      8.7. NanoVelos
      8.7.1. Company Overview
      8.7.2. Technology Portfolio
      8.7.3. Service Portfolio
      8.7.4. Recent Developments and Future Outlook
      8.8. NTT Biopharma
      8.8.1. Company Overview
      8.8.2. Technology Portfolio
      8.8.3. Service Portfolio
      8.8.4. Recent Developments and Future Outlook
      8.9. Organoid-X BioTech
      8.9.1. Company Overview
      8.9.2. Technology Portfolio
      8.9.3. Service Portfolio
      8.9.4. Recent Developments and Future Outlook
      8.10. Vaxinano
      8.10.1. Company Overview
      8.10.2. Technology Portfolio
      8.10.3. Service Portfolio
      8.10.4. Recent Developments and Future Outlook

      9. PARTNERSHIPS AND COLLABORATIONS

      10. PATENT ANALYSIS

      11. NANOPARTICLE EVALUATION FRAMEWORK

      12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

      13. CASE STUDY: TECHNOLOGY LICENSING DEALS

      14. CONCLUSION

      15. EXECUTIVE INSIGHTS

      16. APPENDIX 1: TABULATED DATA

      17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

      For more information about this report visit https://www.researchandmarkets.com/r/y3rtzs

      About ResearchAndMarkets.com
      ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected]
       
      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900
       
      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.